Workshop summary: hormonal suppression in the neoadjuvant setting and advanced disease.
For advanced prostate cancer, hormonal suppression has long played an important role in patient management. Furthermore, the concept of combined androgen blockade using a luteinizing hormone-releasing hormone agonist in combination with an antiandrogen such as flutamide is gaining increasing acceptance. The novel regimen of finasteride (a 5-alpha-reductase inhibitor) plus flutamide may also have a role to play in the future. In the neoadjuvant setting, androgen suppression prior to radical prostatectomy is a novel approach. This strategy aims to reduce the size of the tumor as much as possible, hopefully downstaging the disease, and thus increasing the chances of a successful outcome at operation. Data from studies presented at this symposium revealed a clear reduction in tumor size by this method but the effects on both staging of disease and long-term outcome were not so definitive. Questions were put to the audience and the expert panel to assess their opinion of hormonal therapy and staging techniques, both in the neoadjuvant and advanced disease settings.
Schulman
C C
CC
Department of Urology, University Clinics of Brussels, Erasme Hospital, Belgium.
Debruyne
F M
FM
Ekman
P
P
Labrie
F
F
D000726:Androgen Antagonists / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000628:therapy*
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone